DCM
ADVM

DAFNA Capital Management’s Adverum Biotechnologies ADVM Stock Holding History

DAFNA Capital Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-14,060
Closed -$444K – 79
2016
Q2 		$444K Hold
14,060
– – 0.35% 62
2016
Q1 		$727K Hold
14,060
– – 0.63% 45
2015
Q4 		$1.34M Hold
14,060
– – 1.19% 27
2015
Q3 		$1.16M Buy
+14,060
New +$1.8M 1.15% 27

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

DAFNA Capital Management's ADVM Position: Q3 2016 in Review

DAFNA Capital Management sold out of Adverum Biotechnologies (ADVM) in Q3 2016, closing a stake of 14,060 shares — an estimated $444K sold.

DAFNA Capital Management first reported a position in ADVM in Q3 2015 and held it in 4 quarters. The position peaked at $1.34M in Q4 2015. 76 funds tracked by Wall St. Rank hold ADVM as of Q3 2016.

  • DAFNA Capital Management reported no remaining Adverum Biotechnologies position as of Q3 2016 after selling out during the quarter.
  • DAFNA Capital Management sold 14,060 Adverum Biotechnologies shares in Q3 2016, an estimated $444K.
  • DAFNA Capital Management first reported a position in Adverum Biotechnologies in Q3 2015 and held it in 4 quarters.
  • DAFNA Capital Management's Adverum Biotechnologies position peaked at $1.34M in Q4 2015.
  • 76 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2016.

Based on DAFNA Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.